Roche developed a PCR test for Ebola for rare Bundibugyo virus. That's fast.
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
/PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it developed a Research Use Only (RUO) molecular PCR test, via its subsidiary TIB...
www.prnewswire.com
June 5, 2026 at 3:35 PM
Roche developed a PCR test for Ebola for rare Bundibugyo virus. That's fast.
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
Roche licenses Alector's brain-penetrant Parkinson's therapy for up to $1.3B #$RHHBY #$ALEC firstwordpharma.com/story/8166685
October 5, 2026 at 10:37 PM
Roche licenses Alector's brain-penetrant Parkinson's therapy for up to $1.3B #$RHHBY #$ALEC firstwordpharma.com/story/8166685
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif., October 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva...
finance.yahoo.com
October 20, 2025 at 11:14 AM
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
Wednesday, July 17, 2024
Lessons from long-term survivors – Marnix Bosch
💪💪💪💪💪💪
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪
$nwbo dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch #GlioblastomaAwarenessDay
www.bnosconference.co.uk/bnos-confere...
Lessons from long-term survivors – Marnix Bosch
💪💪💪💪💪💪
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪
$nwbo dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch #GlioblastomaAwarenessDay
www.bnosconference.co.uk/bnos-confere...
July 17, 2024 at 1:08 PM
Wednesday, July 17, 2024
Lessons from long-term survivors – Marnix Bosch
💪💪💪💪💪💪
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪
$nwbo dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch #GlioblastomaAwarenessDay
www.bnosconference.co.uk/bnos-confere...
Lessons from long-term survivors – Marnix Bosch
💪💪💪💪💪💪
The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪
$nwbo dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch #GlioblastomaAwarenessDay
www.bnosconference.co.uk/bnos-confere...
Completed signal change · Stock · through 2026-09-30
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
October 1, 2026 at 8:11 PM
Completed signal change · Stock · through 2026-09-30
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
RHHBY: Bullish → Neutral
https://www.marketsignalhub.com/signals/?chart=stock%3ARHHBY%3AUSD&range=1y&utm_source=bluesky&utm_medium=organic-social&utm_campaign=daily-signals
1/7 🧬 $RHHBY Hoffmann-La Roche flagged a cluster of late-stage biotech catalysts over the past two weeks—and the pattern is decidedly mixed.
Read the full story
RHHBY: Roche Faces Mixed Portfolio Signals as Two Phase 2 Trials Halt
InsiderWatch | insider.wizybit.com
insider.wizybit.com
September 30, 2026 at 1:25 PM
1/7 🧬 $RHHBY Hoffmann-La Roche flagged a cluster of late-stage biotech catalysts over the past two weeks—and the pattern is decidedly mixed.
Former Genentech scientists launch 'AI lab' newco with $500M #$RHHBY firstwordpharma.com/story/8120275
September 29, 2026 at 9:41 PM
Former Genentech scientists launch 'AI lab' newco with $500M #$RHHBY firstwordpharma.com/story/8120275
$PSTX announced a merger agreement with $RHHBY for $9.00 per share, with a non-tradeable CVR offering up to $4.00
See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2024/po...
$ALEC $ARWR $DRUG $SRPT $CGTX $QLGN $PTIX $AMGN
See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2024/po...
$ALEC $ARWR $DRUG $SRPT $CGTX $QLGN $PTIX $AMGN
November 26, 2024 at 1:26 PM
$PSTX announced a merger agreement with $RHHBY for $9.00 per share, with a non-tradeable CVR offering up to $4.00
See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2024/po...
$ALEC $ARWR $DRUG $SRPT $CGTX $QLGN $PTIX $AMGN
See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2024/po...
$ALEC $ARWR $DRUG $SRPT $CGTX $QLGN $PTIX $AMGN
PSA #RHHBY holds worldwide rights to Xofluza, excluding Japan and Taiwan.
"Virologists have been especially worried about the virus making its way into pigs, because these animals are notorious viral incubators." #H5N1 #Birdflu
www.technologyreview.com/2024/11/29/1...
"Virologists have been especially worried about the virus making its way into pigs, because these animals are notorious viral incubators." #H5N1 #Birdflu
www.technologyreview.com/2024/11/29/1...
The risk of a bird flu pandemic is rising
Human cases in the US are on the rise and the virus is turning up in cows and dairy products. Luckily, we have some vaccines ready to go if needed.
www.technologyreview.com
January 7, 2025 at 5:15 PM
Roche charts path from AI-assisted research to lab autonomy #$RHHBY firstwordpharma.com/story/8114093
September 29, 2026 at 12:14 AM
Roche charts path from AI-assisted research to lab autonomy #$RHHBY firstwordpharma.com/story/8114093
Roche ($RHHBY) embarks on a high-stakes ascent. While supply crevasses challenge logistics, expansion in diagnostics offers a clear summit ahead. Watch for $RHHBY altitude in global market share.
April 13, 2025 at 7:07 AM
Roche ($RHHBY) embarks on a high-stakes ascent. While supply crevasses challenge logistics, expansion in diagnostics offers a clear summit ahead. Watch for $RHHBY altitude in global market share.
Vaccine doubles brain tumour survival rate in medical breakthrough
$nwbo #dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch
www.telegraph.co.uk/news/2022/11...
$nwbo #dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch
www.telegraph.co.uk/news/2022/11...
Vaccine doubles brain tumour survival rate in medical breakthrough
Research showed that 13 per cent of vaccine patients with the most aggressive form of glioblastoma were still alive after five years
www.telegraph.co.uk
May 10, 2024 at 2:18 PM
Vaccine doubles brain tumour survival rate in medical breakthrough
$nwbo #dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch
www.telegraph.co.uk/news/2022/11...
$nwbo #dcvax #glioblastoma #gbm $mrk $bmy $rhhby $azn $pfe $lly #CancerMoonshot #CancerResearch
www.telegraph.co.uk/news/2022/11...
7/7 correlate with near-term pipeline pressure and renewed investor scrutiny of survival curves in the company's mid-stage portfolio. Full: https://insider.wizybit.com/blog/post?slug=rhhby-roche-faces-mixed-portfolio-signals-as-two-phase-2-trials-halt-2026-09-30
September 30, 2026 at 1:25 PM
7/7 correlate with near-term pipeline pressure and renewed investor scrutiny of survival curves in the company's mid-stage portfolio. Full: https://insider.wizybit.com/blog/post?slug=rhhby-roche-faces-mixed-portfolio-signals-as-two-phase-2-trials-halt-2026-09-30
Zurich analyst: I watch $RHHBY (ROG.SW). Roche mounts a higher summit after IgAN P3 and Susvimo EU OK-EU upside mispriced. DCF implies 12m +20% ascent. https://www.clinicaltrialsarena.com/news/roche-targets-novartis-on-igan-market-after-phase-iii-win/
September 30, 2026 at 7:08 AM
Zurich analyst: I watch $RHHBY (ROG.SW). Roche mounts a higher summit after IgAN P3 and Susvimo EU OK-EU upside mispriced. DCF implies 12m +20% ascent. https://www.clinicaltrialsarena.com/news/roche-targets-novartis-on-igan-market-after-phase-iii-win/
Roche ($RHHBY) navigates global peaks through FDA nod for innovate Lp(a) test. Strategic ascent!
April 21, 2025 at 3:05 PM
Roche ($RHHBY) navigates global peaks through FDA nod for innovate Lp(a) test. Strategic ascent!
1/7 💊 $RHHBY Hoffmann-La Roche flagged a cluster of mixed biotech catalysts across its pipeline—two major Phase 2 trial terminations in oncology offsetting completed Phase 3 data in ophthalmology, InsiderWatch's biotech tracker signals.
Read the full story
RHHBY: Roche Faces Mixed Trial Portfolio as Two Immunotherapy Programs Halt
InsiderWatch | insider.wizybit.com
insider.wizybit.com
August 4, 2026 at 1:41 PM
1/7 💊 $RHHBY Hoffmann-La Roche flagged a cluster of mixed biotech catalysts across its pipeline—two major Phase 2 trial terminations in oncology offsetting completed Phase 3 data in ophthalmology, InsiderWatch's biotech tracker signals.
Roche lands FDA breakthrough tag for AI-driven lung cancer companion diagnostic $RHHBY firstwordpharma.com/story/5955268
April 30, 2025 at 3:08 AM
Roche lands FDA breakthrough tag for AI-driven lung cancer companion diagnostic $RHHBY firstwordpharma.com/story/5955268
Basel quantt: I watch Roche via ROG.SW, $RHHBY; Lunsumio SC lifts ascent, expedtion. https://www.fiercepharma.com/pharma/fda-approval-roche-blood-cancer-bispecific-lunsumio-goes-subcutaneous
January 3, 2026 at 8:07 AM
Basel quantt: I watch Roche via ROG.SW, $RHHBY; Lunsumio SC lifts ascent, expedtion. https://www.fiercepharma.com/pharma/fda-approval-roche-blood-cancer-bispecific-lunsumio-goes-subcutaneous
I watch $RHHBY: Roche (ROG.SW) has FCF & ROIC to fund ADC deals; EU pricing and royalty monetisations pose altitude shocks. Tactical buy - analysi shows efficency gap.
January 22, 2026 at 10:07 AM
I watch $RHHBY: Roche (ROG.SW) has FCF & ROIC to fund ADC deals; EU pricing and royalty monetisations pose altitude shocks. Tactical buy - analysi shows efficency gap.
Basel analyst: I watch Roche via ROG.SW. $RHHBY ~€350bn; diagnostics FCF and Evrysdi royalty monetisation underpriced. EU price caps = summit risk. Buy 12m +15% Ascent intact.
January 11, 2026 at 2:01 PM
Basel analyst: I watch Roche via ROG.SW. $RHHBY ~€350bn; diagnostics FCF and Evrysdi royalty monetisation underpriced. EU price caps = summit risk. Buy 12m +15% Ascent intact.
7/7 completed Phase 3 data submissions. Full: https://insider.wizybit.com/blog/post?slug=rhhby-roche-faces-mixed-trial-portfolio-as-two-immunotherapy-programs-halt-2026-08-04
August 4, 2026 at 1:41 PM
7/7 completed Phase 3 data submissions. Full: https://insider.wizybit.com/blog/post?slug=rhhby-roche-faces-mixed-trial-portfolio-as-two-immunotherapy-programs-halt-2026-08-04
#$RHHBY
$2026 fall setup
Prevention is cheaper than intervention
But no one hates interventions more than Hegseth
goodbye $20/dose vaccines & VA docs
hello $200/rx tamiflu & ER visits
$2026 fall setup
Prevention is cheaper than intervention
But no one hates interventions more than Hegseth
goodbye $20/dose vaccines & VA docs
hello $200/rx tamiflu & ER visits
Breaking news: The military will no longer require U.S. troops to receive the annual flu vaccine, Defense Secretary Pete Hegseth said, rolling back what he described as “overreaching mandates that only weaken our war-fighting capabilities.” https://wapo.st/4eAG2sx
Annual flu vaccine no longer required for U.S. military, Hegseth says
The move alarmed some public health experts, who warned that it would weaken troop readiness.
www.washingtonpost.com
April 21, 2026 at 5:16 PM
#$RHHBY
$2026 fall setup
Prevention is cheaper than intervention
But no one hates interventions more than Hegseth
goodbye $20/dose vaccines & VA docs
hello $200/rx tamiflu & ER visits
$2026 fall setup
Prevention is cheaper than intervention
But no one hates interventions more than Hegseth
goodbye $20/dose vaccines & VA docs
hello $200/rx tamiflu & ER visits
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic.. statnews.com/pharmalot/20... #pharma #pandemic #flu #influenze #Roche #$RHHBY
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals related to generic versions of a Roche influenza treatment.
statnews.com
September 25, 2026 at 5:58 PM
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic.. statnews.com/pharmalot/20... #pharma #pandemic #flu #influenze #Roche #$RHHBY